U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07384975) titled 'A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa' on Jan. 26.
Brief Summary: The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseli...